Cargando…

No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice

Rasagiline, a monoamine oxidase-B inhibitor, and bis(propyl)-cognitin (B3C), a novel dimer are reported to be neuroprotective. Herein, the synergistical neuroprotection produced by rasagiline and B3C was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice of Parkinsonism...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Cheng-you, Guo, Bao-jian, Cai, Wei, Cui, Wei, Mak, Shing-hung, Wang, Yu-qiang, Lee, Simon Ming-yuen, Han, Yi-fan, Zhang, Zai-jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020835/ https://www.ncbi.nlm.nih.gov/pubmed/27651784 http://dx.doi.org/10.4103/1673-5374.189201

Ejemplares similares

Molecular Targets of Bis (7)-Cognitin and Its Relevance in Neurological Disorders: A Systematic Review
por: Sánchez-Vidaña, Dalinda Isabel, et al.
Publicado: (2019)

Protection against β-amyloid-induced synaptic and memory impairments via altering β-amyloid assembly by bis(heptyl)-cognitin
por: Chang, Lan, et al.
Publicado: (2015)

Rasagiline in treatment of Parkinson’s disease
por: Nayak, Lakshmi, et al.
Publicado: (2008)

The role of rasagiline in the treatment of Parkinson’s disease
por: Leegwater-Kim, Julie, et al.
Publicado: (2010)

Rasagiline Withdrawal Syndrome in Parkinson’s Disease
por: Solla, Paolo, et al.
Publicado: (2022)

Adjunctive therapy in Parkinson’s disease: the role of rasagiline
por: Gaines, Kathryn D, et al.
Publicado: (2012)

Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells
por: Chau, K.Y., et al.
Publicado: (2010)

From a Parkinson's disease expert: Rasagiline and the Future of Therapy
por: Lakhan, Shaheen E
Publicado: (2007)

Role of rasagiline in treating Parkinson’s disease: Effect on disease progression
por: Malaty, Irene A, et al.
Publicado: (2009)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature
por: Pistacchi, Michele, et al.
Publicado: (2013)

Parkinson's disease and dopaminergic neurons
Publicado: (2012)

Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease
por: Petit, Géraldine H., et al.
Publicado: (2013)

Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
por: Schettino, Carla, et al.
Publicado: (2016)

Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study
por: Peretz, Chava, et al.
Publicado: (2016)

Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
por: Mutti, Carlotta, et al.
Publicado: (2022)

Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson’s Disease through Activating Mitophagy
por: Lin, Ming-Wei, et al.
Publicado: (2019)

Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
por: Mamelak, Mortimer
Publicado: (2018)

Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson’s disease
por: Oka, Hisayoshi, et al.
Publicado: (2021)

Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Kano, Osamu, et al.
Publicado: (2022)

Curcumin modulation of L-dopa and rasagiline-induced neuroprotection in rotenone model of Parkinson’s disease
por: El-Shamarka, Marwa El-Sayed, et al.
Publicado: (2023)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson’s Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study
por: Su, Wen, et al.
Publicado: (2023)

Vulnerability of Mesostriatal Dopaminergic Neurons in Parkinson's Disease
por: González-Hernández, Tomás, et al.
Publicado: (2010)

Linezolid and Rasagiline – A culprit for serotonin syndrome
por: Hisham, Mohamed, et al.
Publicado: (2016)

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
por: Finberg, John P.M.
Publicado: (2010)

Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson’s disease
por: Jiang, Ying, et al.
Publicado: (2017)

Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China
por: Zhang, Zhenxin, et al.
Publicado: (2018)

Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Roles of FGF20 in dopaminergic neurons and Parkinson's disease
por: Itoh, Nobuyuki, et al.
Publicado: (2013)

A pharmacodynamic investigation to assess the synergism of orbifloxacin and propyl gallate against Escherichia coli
por: Abbas, Muhammad Aleem, et al.
Publicado: (2022)

Methyl 3,4-bis(cyclopropylmethoxy)benzoate
por: Cheng, Xian-Chao, et al.
Publicado: (2011)

Engineering of Reductive Aminases for Asymmetric Synthesis of Enantiopure Rasagiline
por: Zhang, Kai, et al.
Publicado: (2021)

Dexmedetomidine protects against degeneration of dopaminergic neurons and improves motor activity in Parkinson's disease mice model
por: Zhang, Bao-ping, et al.
Publicado: (2021)

Crystal structure of bis(diisopropylammonium) molybdate
por: Sarr, Bougar, et al.
Publicado: (2018)

A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients
por: Barone, P, et al.
Publicado: (2015)

Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study
por: Cereda, Emanuele, et al.
Publicado: (2017)

Src Inhibition Attenuates Neuroinflammation and Protects Dopaminergic Neurons in Parkinson’s Disease Models
por: Yang, Hanyu, et al.
Publicado: (2020)

Dopaminergic Neuronal Imaging in Genetic Parkinson's Disease: Insights into Pathogenesis
por: McNeill, Alisdair, et al.
Publicado: (2013)

Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson’s Disease
por: Song, Juhyun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9ifk45a4q6lkkgss1e9g67s65i